The impact of rosuvastatin on inflammatory markers in L-NAME induced hypertensive rats

Background and objective: Many clinical trials have revealed that HMG-CoA reductase inhibitors (statins) anti-inflammatory effects through their pleiotropic activities there by decreasing the risk of cardiovascular disease (CVD). This study intended to evaluate effect rosuvastatin on level inflammatory markers (hsCRP, IL-6, sCD40L, Lp-PLA2, cystatin C) in normotensive hypertensive rats. Methods: Twenty-four male Wister rats were divided into two groups twelve. Group 1 consisted rats, while 2 served as model. Each group was further subdivided groups. Subgroup A control which received only placebo subgroup B treatment arm 10mg/kg daily for 4 weeks. Results: Rosuvastatin did not significantly affect blood pressure heart rate both The Lp-PLA2) increased sCD40L C change. lowered model However, hsCRP non-significantly reduced rosuvastatin. In treated with rosuvastatin, reduced. Conclusion: decreased produced a reduction C. Our results suggest an hypertention markers.